Sofinnova Partners and New Enterprise Associates have co-led an oversubscribed series A round for Polyneuron Pharmaceuticals, spun out of University of Basel.

Polyneuron Pharmaceuticals, a Switzerland-based autoimmune diseases treatment developer spun out of University of Basel, today closed a CHF22.5m ($22.5m) series A round co-led by Sofinnova Partners and New Enterprise Associates (NEA).
Unnamed existing shareholders also contributed to the oversubscribed round.
Founded in 2014, Polyneuron is development treatments for autoimmune disorders such as anti-MAG neuropathy, a very rare conditions that causes the immune system to attack myelin-associated glycoprotein (MAG), essential to a healthy peripheral nervous system.
The proposed…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in